France has begun reimbursing the GLP-1 obesity drugs Wegovy and Mounjaro through national health insurance at 65% for eligible patients with severe obesity or obesity plus comorbidities, marking a major policy shift.

The reimbursement took effect this Monday after two decrees published in late May, with initial coverage applying to those meeting strict criteria set by social security.

Estimate suggests about one million people could be eligible, although health authorities expect actual numbers to be lower and project the total cost to the national insurance around 100 million euros in 2027.

In the short term, demand will not surge because not all eligible patients can be treated immediately; many currently seeking treatment may still pay out of pocket.

Healthcare experts and insurers are considering accelerating the rollout of oral versions and broader coverage as the system adapts to demand and cost considerations.

Reporting noted to be sourced from Le Figaro, with some content behind a paywall due to subscription prompts.

The reimbursement is described as a European milestone that could be transformative for eligible individuals undergoing these therapies.

Personal case: Léa Boulanger, 29, treated with Mounjaro since December, pays about 279 euros monthly and emphasizes ongoing medical follow-up and trust in her physician.

Officials anticipate roughly one million potential beneficiaries, but actual uptake will be lower, and costs to Assurance Maladie are being actively monitored.

Before reimbursement, patients commonly paid up to around 500 euros monthly out of pocket; the new scheme aims to reduce that burden for eligible users.

The reimbursement requires accompanying lifestyle changes, including calorie restriction and increased physical activity, though enforcement of these criteria may be limited in practice.

Endocrinologists report a surge in inquiries and interest from patients seeking reimbursement, signaling strong demand for these treatments.